Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gilbertas Rimkus

Surgery Conway, SC Medical Doctor

NPI 1326126301 CMS profile 15475

2361 Cypress Cir, Conway, SC 29526

Open in the dashboard

General payments

$12,800

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gilbertas Rimkus of Conway, SC is reported in the CMS Open Payments database as having received $12,800 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $736 11
2024 General $160 7
2023 General $363 8
2022 General $25 1
2021 General $24 1
2020 General $673 8
2019 General $10,821 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gilbertas Rimkus
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Gilbertas Rimkus were reported at $736. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Gilbertas Rimkus Surgery median Middle half National median
2019 $10,821 $253 $82–$1,521 $163
2020 $673 $131 $40–$706 $114
2021 $24 $168 $50–$904 $132
2022 $25 $224 $76–$1,218 $149
2023 $363 $253 $82–$1,255 $160
2024 $160 $279 $90–$1,381 $164
2025 $736 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $10,146 25 payments
  2. Allergan Inc. $1,512 8 payments
  3. TELA Bio, Inc. $674 10 payments
  4. Davol Inc. $76 2 payments
  5. PolyNovo North America LLC $65 4 payments
  6. Stryker Corporation $60 2 payments
  7. Ethicon US, LLC $59 2 payments
  8. Innocoll Incorporated $48 2 payments
  9. Kerecis Limited $45 2 payments
  10. Portola Pharmaceuticals, Inc. $32 1 payment
  11. Other $84 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $7,233 3 payments
  2. Travel and Lodging $4,009 13 payments
  3. Food and Beverage $1,558 48 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $10,146 25 payments
  2. STRATTICE $1,512 8 payments
  3. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $575 6 payments
  4. OviTex 2S $99 4 payments
  5. Phasix Mesh $76 2 payments
  6. Kerecis SurgiClose Wound Care $45 2 payments
  7. Kerecis SurgiClose Wound Care $45 2 payments
  8. Kerecis SurgiClose Wound Care $45 2 payments
  9. Kerecis GraftGuide $45 2 payments
  10. Kerecis SurgiClose Wound Care $45 2 payments
  11. Other $437 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

275

Median for General Surgery: 59

Drug cost

$1,634

Median for General Surgery: $393

Branded share of claims

59.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $462
Hydrocortisone Generic 34 $388
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 69 $330
Metronidazole Generic 17 $133
Doxycycline Hyclate Generic 20 $131
Silver Sulfadiazine Generic 11 $91
Levofloxacin Generic 16 $58
Tramadol Hcl Generic 14 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$97,949

Medicare's payments for the services billed

Medicare patients

325

Average age 73

Services billed

723

156 women, 169 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 29%
Ischemic heart disease 24%
Depression 20%
Chronic kidney disease 19%
Atrial fibrillation 18%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record